NCT06787612

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 220 (estimated)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations

Conditions

• Ovarian Cancer
• Fallopian Tube Cancer
• Primary Peritoneal Cancer

Interventions

Type	Name	Description
DRUG	Ubamatamab	Administered per the protocol
DRUG	Bevacizumab	Administered per the protocol
DRUG	Cemiplimab	Administered per the protocol
DRUG	Fianlimab	Administered per the protocol
DRUG	PLD	Administered per the protocol
DRUG	Sarilumab	Administered per the protocol

Timeline

• Start date: 2025-05-28
• Primary completion: 2028-10-30
• Completion: 2028-10-30
• First posted: 2025-01-22
• Last updated: 2026-04-08

Locations

50 sites across 5 countries: United States, Canada, South Korea, Taiwan, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study